Stockscreener 앱 받기
13.85
1.91%
-0.27
시장 영업 전:
13.56
-0.29
-2.09%
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Re - The National Law Review
(ARCT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A Quick Look at Today's Ratings for Arcturus Therapeutics(ARCT.US), With a Forecast Between $20 to $41 - Moomoo
Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform - Yahoo Finance
Arcturus Therapeutics Shares Rise After OTC Deficiency Data, Citigroup Upgrade - marketscreener.com
Why Is Arcturus Therapeutics Stock Gaining Thursday? - Benzinga
Arcturus Gets Citi Upgrade After Positive Liver Disease Study Data – But BTIG Says Therapy’s Benefit Is Hard To Measure - Yahoo Finance
ARCT Upgraded by Citigroup -- Price Target Raised to $20.00 - GuruFocus
ARCT Looks 565.3% Overvalued on GF Value™ - GuruFocus
Arcturus stock upgraded to Buy at Citi (ARCT:NASDAQ) - Seeking Alpha
Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday - Benzinga
Citigroup Upgrades Arcturus Therapeutics to Buy From Neutral, Adjusts PT to $20 From $8 - marketscreener.com
ARCT Maintained by BTIG -- Price Target Lowered to $20 - GuruFocus
Citi Upgrades Arcturus Therapeutics(ARCT.US) to Buy Rating, Raises Target Price to $20 - Moomoo
Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics PlatformSlideshow (NASDAQ:ARCT) 2026-09-24 - Seeking Alpha
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform - BioSpace
Arcturus Therapeutics Releases ARCT-810 Phase 2 Clinical Results and mRNA Platform Update - Kalkine Media
ARCT Looks 521.5% Overvalued on GF Value™ - GuruFocus
Arcturus sees positive results from mid-stage trial of RCT-810 in OTC deficiency - Seeking Alpha
Arcturus Showcases Phase 2 ARCT-810 Data, mRNA Advances - TipRanks
Arcturus Therapeutics Holdings Inc to Host Virtual Presentation Transcript - GuruFocus
Arcturus Therapeutics Holdings Inc. Announces Interim Arct-810 Phase 2 Results and Introduces Lunar 2.0 Next-Generation Mrna Delivery Platform - marketscreener.com
Arcturus Therapeutics Holdings Inc. entered into a definitive agreement to acquire MyNeo NV. - marketscreener.com
Arcturus Therapeutics (ARCT) Slips 2.11% to $14.38 as Shares Drift Toward Range SupportInside Day Breakout - siam.in
Arcturus Therapeutics: A Speculative Buy For Their OTC Deficiency Program (NASDAQ:ARCT) - Seeking Alpha
SNBIF Stock Price and Chart — OTC:SNBIF - TradingView
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform - Yahoo Finance
ARCT Stock Price and Chart — NASDAQ:ARCT - TradingView
Trading the Move, Not the Narrative: (ARCT) Edition - Stock Traders Daily
Arcturus Therapeutics Holdings Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Arcturus Therapeutics at cantoral global healthcare conference: data catalysts ahead By Investing.com - Investing.com South Africa
Arcturus Therapeutics at cantoral global healthcare conference: data catalysts ahead - Investing.com India
Arcturus Therapeutics at Citi summit: two catalysts, one pivotal year By Investing.com - Investing.com Canada
Arcturus Therapeutics at Citi summit: two catalysts, one pivotal year - Investing.com
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. (ARCT) Peer Comparison – Compare with Others - Value Research
Arcturus Therapeutics Holdings Inc (ARCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Raises Target Price to $41 - Moomoo
Why is Arcturus Therapeutics stock surging today? By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Arcturus Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Arcturus Therapeutics Holdings Inc. (ARCT) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Arcturus Therapeutics (ARCT) Drops 6% as Biotech Sector Headwinds IntensifyWyckoff Upthrust - dars.gov.et
Arcturus, Moderna down on BioNTech trial setback (ARCT:NASDAQ) - Seeking Alpha
Arcturus Therapeutics Holdings Inc. (ARCT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Arcturus Therapeutics Highlights ARCT-810 Progress at Metabolic Symposium - TipRanks
Arcturus (ARCT) Results Check: EPS Clears the Reported Estimate; Market Response: Shares Finish 22.38% Up for the Current SessionEarnings Power Value - vinanet.vn
ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’ - Stocktwits
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
ARCT Defies mRNA Selloff And Extends Rally As Moderna, BioNTech Shares Pull Back - Yahoo Finance
Arcturus (ARCT) Results Review: EPS Comes in Above Forecast in the Latest Reading; Stock Move: The Market Price Advances 19.85% on the DayGeographic Revenue Trends - Vinanet
ARCT Stock Jumps As Vaccine Rights Return And Cash Pile Grows - StocksToTrade
ARCT Stock Jumps As Canaccord Backs Vaccine Reset - timothysykes.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Liquidity Mapping Around (ARCT) Price Events - Stock Traders Daily
We're Keeping An Eye On Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate - Moomoo
Dimensional Fund Advisors LP Decreases Holdings in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Arcturus Therapeutics (ARCT) Surges 5.92% to $8.05, Approaches Key Resistance at $8.45Low Volatility Picks - vinanet.vn
HC Wainwright Has Optimistic Outlook of ARCT Q3 Earnings - MarketBeat
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline - MarketBeat
3.06%
2.55%
자본화:
|
볼륨(24시간):